

CONTENTS

List of tables

List of figures

Abbreviations

Preface

Chapters	Page No.
1. Introduction.....	1
1.1. Antimicrobial resistance (AMR).....	1
1.1.1. AMR threaten global health and future treatments.....	2
1.1.1.1. Immediate health threats.....	3
1.1.1.2. Long-term risks to future treatments.....	3
1.1.2. Strategies to mitigate AMR.....	4
1.1.3. AMR in key pathogens: mechanisms and implications.....	4
1.2. Nanoparticles as an alternative treatment to AMR.....	7
1.2.1. Metallic nanoparticles.....	8
1.2.2. Bimetallic nanoparticles.....	9
1.3. Chitosan.....	10
1.3.1. N,N,N-Trimethyl chitosan.....	11
1.3.1.1. Structure and advantages.....	12
1.3.1.2. TMC-based bimetallic nanoparticles.....	12
1.3.1.3. Antimicrobial uses of TMC.....	13
1.3.1.4. Applications.....	13
1.3.1.5. Mechanisms of antimicrobial action.....	13
1.3.1.6. Safety and biocompatibility.....	14
1.3.2. Carboxymethyl chitosan.....	14
1.3.2.1. Structure and advantages.....	15
1.3.2.2. CMC-based bimetallic nanoparticles.....	15
1.3.2.3. Antimicrobial uses and mechanism of action.....	16
1.4. Nanofibers.....	16
1.4.1. Synthesis and structural features of nanofibers.....	17
1.4.2. Functional applications of nanofibers.....	18
1.4.3. Antimicrobial and bactericidal mechanisms of nanofibers.....	19
1.4.4. Nanofibers loaded with nanoparticles.....	19
1.4.5. Nanofibers as wound dressing for tissue engineering.....	20
2. Literature Review.....	22
2.1. Antimicrobial resistance in wound infections: A global crisis.....	22
2.1.1. Epidemiology of AMR in wound infections.....	22
2.1.1.1. Prevalence of multidrug-resistant pathogens.....	22

2.1.1.2. Risk factors driving AMR in wounds.....	22
2.1.2. Mechanisms of AMR in wound pathogens.....	22
2.1.2.1. Biofilm formation and persistence.....	22
2.1.2.2. Genetic and enzymatic resistance.....	23
2.1.2.3. Synergistic resistance in polymicrobial infections..	24
2.1.3. Clinical and socioeconomic impact.....	24
2.1.3.1. Mortality and morbidity.....	24
2.1.3.2. Economic burden.....	24
2.1.3.3. Disproportionate impact on developing regions....	24
2.1.4. Strategies to mitigate AMR in wound care.....	25
2.1.4.1. Diagnostic and surveillance innovations.....	25
2.1.4.2. Antimicrobial stewardship and alternatives.....	25
2.2. Bimetallic nanoparticles: synergistic antimicrobial strategies.....	25
2.2.1. Rationale for bimetallic nanoparticles in AMR therapy.....	25
2.2.2. Synthesis and characterization of bimetallic nanoparticles..	26
2.2.3. Mechanisms of synergistic antimicrobial action.....	28
2.2.3.1. Enhanced bactericidal activity.....	28
2.2.3.2. Biofilm inhibition.....	29
2.2.4. Comparative efficacy and cytotoxicity.....	29
2.3. Chitosan and chitosan derivatives for nanoparticles.....	29
2.3.1. Synthesis methods for chitosan-based nanoparticles.....	30
2.3.1.1. Ionic gelation and crosslinking.....	30
2.3.1.2. Green synthesis.....	30
2.3.1.3. Ultrasonication-assisted techniques.....	30
2.3.2. Characterization and structural insights.....	30
2.3.3. Mechanisms of antimicrobial action.....	31
2.3.4. Applications in drug delivery and wound care.....	31
2.3.5. TMC: synthesis and applications.....	32
2.3.6. CMC: synthesis and functional advantages.....	33
2.4. Nanofibers as advanced wound dressings.....	35
2.4.1. Structural and functional advantages of nanofibers.....	35
2.4.1.1. ECM mimicry and cellular support.....	35
2.4.1.2. Versatile fabrication techniques.....	36
2.4.2. Antimicrobial mechanisms and bioactive delivery.....	36
2.4.2.1. Intrinsic and loaded antimicrobial activity.....	36
2.4.2.2. Biofilm disruption.....	36
2.4.3. Clinical efficacy and preclinical success.....	37
2.4.3.1. <i>In vivo</i> and clinical outcomes.....	37
2.4.3.2. Anti-inflammatory and anti-scarring properties....	37
2.4.4. Challenges and limitations.....	37
2.5. Integration of Au-Ag-NPs into nanofibers—design and efficacy...	38
2.5.1. Design strategies for Au-Ag-NPs loaded nanofibers.....	38
2.6. Preclinical and clinical evidence for bimetallic Au-Ag nanoparticles in wound healing.....	39
2.6.1. <i>In vitro</i> evidence: antimicrobial efficacy and mechanisms...	39
2.6.2. <i>In vivo</i> preclinical evidence: animal models.....	40
2.6.3. Clinical evidence: transitioning from bench to bedside.....	40

2.6.4. Challenges and future directions.....	41
2.7. Future directions and innovations.....	41
2.7.1. Green and sustainable synthesis of bimetallic nanoparticles.....	41
2.7.2. Advanced nanofiber composites and multifunctionality....	42
2.7.3. Smart and responsive wound dressings.....	42
2.7.4. Clinical translation and safety optimization.....	43
2.7.5. Expanding antimicrobial spectrum and personalized medicine.....	43
3. Objectives and plan of work.....	45
3.1. Hypothesis.....	45
3.2. Aims and objectives.....	46
3.3. Plan of work.....	46
4. Nanofibers of N,N,N-trimethyl chitosan capped bimetallic nanoparticles.....	48
4.1. Materials.....	49
4.2. Methods.....	50
4.2.1. Synthesis and characterization of Au-Ag-TMC-NPs.....	50
4.2.1.1. Particle size, PDI, and surface charge.....	52
4.2.1.2. UV-spectroscopy.....	52
4.2.1.3. Transmission electron microscopy analysis.....	52
4.2.1.4. Atomic force microscopy analysis.....	52
4.2.1.5. STEM-EDX analysis.....	53
4.2.2. Antimicrobial activity.....	53
4.2.2.1. Isolation of multidrug-resistant microorganism.....	53
4.2.2.2. Estimation of MIC, MBC and MFC.....	53
4.2.2.3. Disc diffusion assay.....	54
4.2.2.4. Anti-biofilm activity.....	54
4.2.2.5. Live dead cell viability assay.....	55
4.2.2.6. TEM microscopy of microbes.....	56
4.2.2.7. Atomic force microscopy of microbes.....	56
4.2.2.8. Efflux pump gene expression profiling by RTPCR.....	57
4.2.2.9. Hemolysis test.....	58
4.2.3. Preparation and characterization of Au-Ag-TMC-NPs-NFs..	59
4.2.3.1. Electrospinning process.....	59
4.2.3.2. Contact angle measurement.....	61
4.2.3.3. FT-IR analysis.....	61
4.2.3.4. XRD analysis.....	61
4.2.3.5. TEM analysis.....	61
4.2.3.6. SEM analysis.....	61
4.2.3.7. AFM analysis.....	61
4.2.3.8. Water retention capacity.....	62
4.2.3.9. Nanofiber stability and degradation.....	62
4.2.3.10. Thermal stability.....	63
4.2.3.11. <i>In vitro</i> release study.....	63
4.2.3.12. Hemolysis study of nanofibers.....	63
4.2.3.13. Whole blood clotting ability.....	64

4.2.3.14. Thrombus development analysis.....	64
4.2.4. <i>In vivo</i> study of Au-Ag-TMC-NPs-NFs on wound site.....	65
4.2.5. Wound healing study.....	65
4.2.5.1. <i>In vivo</i> wound healing study.....	65
4.2.5.2. Histopathological studies.....	67
4.2.6. <i>In vivo</i> ultrasound/photoacoustic study.....	67
4.2.7. Western blot study of wound marker protein.....	68
4.2.8. Statistical analysis.....	69
4.3. Results.....	69
4.3.1. Characterization of nanoparticles.....	69
4.3.1.1. Particle size, PDI and surface charge.....	69
4.3.1.2. UV/Vis spectroscopy.....	69
4.3.1.3. Transmission electron microscopy analysis.....	70
4.3.1.4. Atomic force microscopy analysis.....	71
4.3.1.5. STEM-EDX analysis.....	72
4.3.2. Antimicrobial activity of nanoparticles.....	72
4.3.2.1. MIC, MBC and MFC.....	72
4.3.2.2. Bacterial susceptibility.....	73
4.3.2.3. Bacterial viability test.....	76
4.3.2.4. Antibiofilm activity.....	80
4.3.2.5. TEM microscopy study of test microbes.....	82
4.3.2.6. mRNA expression of biofilm-inducing efflux pump...	83
4.4. Hemolysis study of nanoparticles.....	85
4.5. Characterization of nanofibers.....	86
4.5.1 Measurement of contact angle.....	86
4.5.2. TEM analysis of Au-Ag-TMC-NPs-NFs.....	86
4.5.3. SEM analysis of Au-Ag-TMC-NPs-NFs.....	87
4.5.4. AFM analysis of Au-Ag-TMC-NPs-NFs.....	88
4.5.5. FT-IR analysis.....	89
4.5.6. XRD analysis.....	89
4.5.7. Thermal stability of nanofibers.....	90
4.5.8. Release study of nanofibers.....	92
4.5.9. Hemolysis study of nanofibers.....	92
4.5.10. Nanofibers pH.....	93
4.5.11. Whole blood clotting ability.....	93
4.5.12. Thrombus formation test.....	95
4.5.13. Water retention capacity.....	95
4.5.14. Stability and degradation studies of nanofibers.....	96
4.6. Wound healing potential study of Au-Ag-TMC-NPs-NFs.....	96
4.7. Western blot study of wound healing marker protein.....	99
4.8. <i>In vivo</i> nanoformulation release study.....	103
4.9. <i>In vivo</i> ultrasound/photoacoustic study.....	104
4.10. Conclusion	110
5. Carboxymethyl chitosan capped bimetallic nanoparticles entrapped in theranostic nanofibers.....	111
5.1. Materials.....	114
5.2. Methods.....	114

5.2.1. Fabrication and characterization of G-S-CMC-Pep-NPs.....	114
5.2.1.1. Size of particle, PDI, and zeta potential.....	116
5.2.1.2. Transmission electron microscopy analysis.....	116
5.2.1.3. Atomic force microscopy analysis.....	116
5.2.1.4. Energy dispersive spectroscopy analysis.....	117
5.2.2. Antimicrobial efficacy.....	117
5.2.2.1. Isolation of MDR microbes.....	117
5.2.2.2. Antimicrobial susceptibility testing.....	118
5.2.2.3. Estimation of MIC and MBC.....	118
5.2.2.4. Disc diffusion method.....	119
5.2.2.5. Antibiofilm assay.....	119
5.2.2.6. Assessment of live and dead cell viability.....	120
5.2.2.7. TEM analysis of microorganisms.....	120
5.2.3. Hemolysis analysis	121
5.2.4. Fabrication and evaluation of G-S-CMC-Pep-NPs-NFs.....	121
5.2.4.1. Electrospinning.....	122
5.2.4.2. Contact angle analysis.....	122
5.2.4.3. Fourier transform infrared investigation.....	122
5.2.4.4. X-ray-diffraction analysis.....	122
5.2.4.5. Evaluation of nanofiber by TEM.....	122
5.2.4.6. Evaluation of nanofiber by SEM.....	123
5.2.4.7. Evaluation of nanofiber by AFM.....	123
5.2.4.8. Water-retention capability.....	123
5.2.4.9. Nanofibers' stability and degradation.....	123
5.2.4.10. <i>In vitro</i> release profile.....	124
5.2.4.11. Nanofibers' hemolysis.....	125
5.2.4.12. Blood clotting study.....	125
5.2.4.13. Thrombus formation study.....	125
5.2.5. Preparation of ultra small magnesium nanoclusters.....	126
5.2.6. <i>In vivo</i> fluorescence imaging of G-S-CMC-Pep-NPs-NFs.....	126
5.2.7. Wound healing investigation.....	127
5.2.7.1. <i>In vivo</i> wound healing investigation.....	127
5.2.7.2. Histopathological studies.....	128
5.2.8. Live ultrasound/photoacoustic investigation.....	129
5.2.9. Western blotting analysis.....	129
5.2.10. Statistical interpretation.....	130
5.3. Results	131
5.3.1. Characterization of nanoparticles.....	131
5.3.1.1. Size of the nanoparticles, PDI and zeta potential.....	131
5.3.1.2. TEM analysis.....	132
5.3.1.3. AFM analysis.....	132
5.3.1.4. EDS analysis.....	132
5.3.2. Antibacterial potential of nanoparticles.....	134
5.3.2.1. Prevalence and resistance rate.....	134
5.3.2.2. MIC and MBC.....	135
5.3.2.3. Bacterial susceptibility.....	137
5.3.2.4. Bacterial viability analysis.....	139

5.3.2.5. Anti-biofilm analysis.....	139
5.3.2.6. TEM investigation of test microorganisms.....	141
5.3.3. Hemolysis analysis of nanoparticles.....	143
5.3.4. Nanofiber characterization.....	144
5.3.4.1 Contact angle measurement.....	144
5.3.4.2. TEM imaging of nanofibers.....	145
5.3.4.3. SEM imaging of nanofibers.....	145
5.3.4.4. AFM imaging of nanofibers.....	146
5.3.4.5. FT-IR investigation.....	147
5.3.4.6. XRD of nanofibers.....	149
5.3.4.7. Aspects of nanofiber release.....	150
5.3.4.8. Hemolytic investigation of nanofibers.....	150
5.3.4.9. pH of nanofibers.....	151
5.3.4.10. Competence in blood clotting.....	152
5.3.4.11. Thrombus formation study.....	153
5.3.4.12. Water retention ability.....	153
5.3.4.13. Characteristics of nanofiber stability and degradation	154
5.3.5. USM nanoclusters.....	154
5.3.6. Wound healing investigation.....	155
5.3.7. Western blotting analysis.....	157
5.3.8. Release profile of nanoformulation via IVIS.....	161
5.3.9. Live ultrasound/photoacoustic investigation.....	164
5.3.10. Conclusion.....	171
6. Summary and conclusions.....	173
7. References.....	175
8. Publication from the research work.....	187
9. Curriculum vitae.....	191